Efficient infection of human natural killer cells with an EBV/retroviral hybrid vector

被引:28
作者
Becknell, B
Trotta, R
Yu, JH
Ding, W
Mao, HC
Hughes, T
Marburger, T
Caligiuri, MA
机构
[1] Ohio State Univ, Ctr Comprehens Canc, Dept Internal Med, Div Hematol Oncol, Columbus, OH 43210 USA
[2] Ohio State Univ, Med Scientist Program, Integrated Biomed Grad Program, Coll Med & Publ Hlth, Columbus, OH 43210 USA
[3] Ohio State Univ, Div Human Canc Genet, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA
关键词
natural killer; NK; NK-92; retrovirus; infection;
D O I
10.1016/j.jim.2004.11.012
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Molecular characterization of human natural killer (NK) cells will require targeted gene delivery to inhibit and activate specific signaling pathways, yet to our knowledge, an effective means to deliver such products for long-term gene expression without disrupting normal cellular processes has not been described. In this study, we have developed a retroviral strategy to effectively express gene products in the NK cell, whereby its effector functions of cytotoxicity and cytokine production remain intact. Using an EBV/retroviral hybrid vector, we demonstrate infection of human peripheral blood NK cells with simultaneous expression of a marker for infection-the enhanced green fluorescent protein (EGFP)-along with various genes of interest. This technique results in successful infection of the CD56(dim) NK population that predominates among human peripheral blood NK and is the effector of antibody-dependent cellular cytotoxicity and natural killing. In addition, we demonstrate infection of the CD56(bright) NK subset as well as the NK-92 cell line. In summary, we have devised an efficient and reproducible methodology for the targeted delivery of gene products to human NK cells that should now provide opportunities to dissect the molecular processes critical to normal NK cell physiology. (C) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:115 / 123
页数:9
相关论文
共 24 条
  • [1] INTERLEUKIN (IL)-15 IS A NOVEL CYTOKINE THAT ACTIVATES HUMAN NATURAL-KILLER-CELLS VIA COMPONENTS OF THE IL-2 RECEPTOR
    CARSON, WE
    GIRI, JG
    LINDEMANN, MJ
    LINETT, ML
    AHDIEH, M
    PAXTON, R
    ANDERSON, D
    EISENMANN, J
    GRABSTEIN, K
    CALIGIURI, MA
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1994, 180 (04) : 1395 - 1403
  • [2] BCR/ABL alters the function of NK cells and the acquisition of killer immunoglobulin-like receptors (KIRs)
    Chiorean, EG
    Dylla, SJ
    Olsen, K
    Lenvik, T
    Soignier, Y
    Miller, JS
    [J]. BLOOD, 2003, 101 (09) : 3527 - 3533
  • [3] Cooper GJS, 2001, AUST J DAIRY TECHNOL, V56, P97
  • [4] Fehniger T A, 2001, Int Rev Immunol, V20, P503, DOI 10.3109/08830180109054417
  • [5] Interleukin-2 and interleukin-15: immunotherapy for cancer
    Fehniger, TA
    Cooper, MA
    Caligiuri, MA
    [J]. CYTOKINE & GROWTH FACTOR REVIEWS, 2002, 13 (02) : 169 - 183
  • [6] Galandrini R, 2001, EUR J IMMUNOL, V31, P2016, DOI 10.1002/1521-4141(200107)31:7<2016::AID-IMMU2016>3.0.CO
  • [7] 2-W
  • [8] Grignani F, 1998, CANCER RES, V58, P14
  • [9] Pivotal role of phosphoinositide-3 kinase in regulation of cytotoxicity in natural killer cells
    Jiang, K
    Zhong, B
    Gilvary, DL
    Corliss, BC
    Hong-Geller, E
    Wei, S
    Djeu, JY
    [J]. NATURE IMMUNOLOGY, 2000, 1 (05) : 419 - 425
  • [10] The T cell activation factor NF-ATc positively regulates HIV-1 replication and gene expression in T cells
    Kinoshita, S
    Su, LS
    Amano, M
    Timmerman, LA
    Kaneshima, H
    Nolan, GP
    [J]. IMMUNITY, 1997, 6 (03) : 235 - 244